Combined androgen deprivation therapy (ADT) and radiotherapy (RT) improves outcomes for intermediate and high-risk prostate cancer. Treatment intensification with abiraterone acetate/prednisone (AAP) provides additional benefit for high-risk disease. We previously reported 3-year outcomes of a single-arm prospective multicenter trial (AbiRT trial) of 33 patients with unfavorable intermediate risk (UIR) and favorable high risk (FHR) prostate cancer undergoing short course, combination therapy with ADT, AAP, and RT. Here we report the final analysis demonstrating a high rate of testosterone recovery (97%) and excellent biochemical progression-free survival (97%) at 5 years. These data support comparative prospective studies of shorter, more potent ADT courses in favorable high-risk prostate cancer.

联合雄激素剥夺疗法 (ADT) 和放射疗法 (RT) 可改善中危和高危前列腺癌的预后。醋酸阿比特龙/泼尼松 (AAP) 强化治疗为高危疾病提供了额外的益处。我们之前报道了一项单臂前瞻性多中心试验（AbiRT 试验）的 3 年结果，该试验对 33 名患有不利中危 (UIR) 和有利高风险 (FHR) 前列腺癌的患者进行短期疗程、ADT、AAP 和RT。在此，我们报告的最终分析表明，睾酮恢复率很高 (97%)，并且 5 年生化无进展生存率极好 (97%)。这些数据支持针对有利的高危前列腺癌进行更短、更有效的 ADT 疗程的比较前瞻性研究。